On the stock market since 2007, it operates in the world of health and science. It has 44 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 6% a year over the last 4 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
This grade is a blend: the profit side is strong, the sales tempo slow.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 18% below its peak. The market has trimmed its expectations for the company.
The company sells $14.1M a year; the problem isn’t sales — it’s costs running above that number.
There is $91.5M in the vault; even if every debt were paid off, $87.3M would remain.
Over the last 12 months, company executives reported 20 buys and 4 sells. Management buying with its own money is usually read as a good sign.
A loss of $33.5M against $14.1M in annual sales.
Right now the product sells for less than it costs to make; every sale deepens the loss.
Costs swallow the gains that sales growth brings in.
On our five-subject report card, ABUS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ABUS is a small company that closed last year at a loss. The road back to profit runs through spending discipline.